Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. (INBX) received a Rule 144 notice relating to a proposed sale of its common stock. A person identified as Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust, has filed to sell 500 shares of Inhibrx Biosciences common stock through Fidelity Brokerage Services LLC.
Inhibrx Biosciences, Inc. (INBX) is the issuer for which a notice has been filed to permit the potential resale of its common stock under Rule 144 on behalf of Kimberly Manhard. The notice covers 500 shares of common stock held in the Kimberly Joan Manhard Revocable Trust. The filing lists an aggregate market value of $57,570.00 for these shares and identifies Fidelity Brokerage Services LLC as the broker, with the notice dated September 8, 2026.
Inhibrx Biosciences, Inc. (INBX) director Jon Faiz Kayyem reported that The Jon F. Kayyem and Paige Gates-Kayyem Family Trust purchased 5,000 shares of common stock on September 8, 2026 at a weighted-average price of $113.52 per share in open-market transactions, with prices ranging from $113.30 to $113.55.
After this purchase, that Family Trust held 424,360 shares indirectly attributed to Kayyem, for which he disclaims beneficial ownership except for any indirect pecuniary interest. Additional indirect holdings reported include 250,000 shares in the Jon Faiz Kayyem Revocable Trust, 250,000 shares in the Paige Gates-Kayyem Revocable Trust, and 69,843 shares in custodial accounts for each of two minor children.
Inhibrx Biosciences, Inc. (INBX) director Douglas Forsyth reported an open-market purchase of company stock through a family trust. On September 8, 2026, the Forsyth Family Trust bought 2,500 shares of common stock at a weighted-average price of $114.6469 per share.
The shares are held indirectly via the Forsyth Family Trust Dated July 20, 2001, of which Forsyth is a trustee and may be deemed to indirectly beneficially own the securities. Following this transaction, the trust held 227,064 shares of Inhibrx Biosciences common stock. The price reflects multiple trades between $114.36 and $114.689 per share, and no Rule 10b5-1 trading plan is reported.
Inhibrx Biosciences, Inc. (INBX) reported that Chief Executive Officer and director Mark P. Lappe, through the Lappe Family Trust, purchased a total of 25,000 shares of common stock on September 8, 2026 in multiple open-market transactions at weighted-average prices around $99–$112 per share. The filing also reports additional indirect holdings in a family trust and a Roth IRA.
Inhibrx Biosciences, Inc. (INBX) reported positive randomized Phase 2 data from its HexAgon study of INBRX-106 plus pembrolizumab in first-line PD-L1–positive metastatic or unresectable recurrent HNSCC. Among 63 evaluable patients at an August 19, 2026 cutoff, the combination achieved a confirmed objective response rate of 48.3% versus 26.5% for pembrolizumab alone, including complete responses in 13.8% of combination patients and none on monotherapy.
Median progression-free survival was 9.6 months for the combination versus 4.9 months for pembrolizumab, with six‑month PFS rates of 72.4% and 42.8%, respectively. In HPV+ patients, cORR was 80.0% vs 33.3%, with 30.0% complete responses and 90.0% six‑month PFS for the combination versus 0% complete responses and 33.0% six‑month PFS for pembrolizumab. The combination’s safety profile was generally manageable, with mostly low‑grade rash, fatigue, and diarrhea.
Based on these results, Inhibrx plans to expand the randomized Phase 2 portion of HexAgon by approximately 50 additional HPV+ OPSCC patients (CPS ≥ 1) to support a potential accelerated regulatory pathway, then initiate a Phase 3 confirmatory trial after alignment with the FDA. INBRX-106 is also being studied in a Phase 1/2 perioperative NSCLC trial with an initial data readout targeted by mid‑2027 and is being positioned for broader use in highly immunogenic tumors and in combination with therapeutic cancer vaccines.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. common stock, representing 9.99% of the class. This percentage is based on 14,717,660 shares outstanding as of August 7, 2026, plus shares issuable under certain warrants.
The Master Fund directly holds 1,297,763 common shares and 732,157 pre-funded warrants, each immediately exercisable at $0.0001 per share. Because of a 9.99% Beneficial Ownership Limitation, the reporting group currently may exercise warrants for only 191,680 shares, and assumes the remaining warrants are not exercisable for ownership-calculation purposes. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to share voting and dispositive power over the same 1,489,443 shares.
Inhibrx Biosciences, Inc. received a large shareholder disclosure from Schonfeld Strategic Advisors LLC, a Delaware limited liability company and investment adviser to several private funds and separately managed accounts. Schonfeld reports beneficial ownership of 781,678 shares of Inhibrx Biosciences common stock, representing 5.33% of the outstanding class. This percentage is based on 14,671,186 shares outstanding as of May 8, 2026, as reported in Inhibrx Biosciences’ quarterly report for the period ended March 31, 2026. Schonfeld has sole voting and dispositive power over these 781,678 shares, while its clients, on whose behalf the securities are held, have the right to receive dividends and sale proceeds. Schonfeld states that the filing should not be construed as an admission that it is the beneficial owner of these securities for any legal purpose.
Inhibrx Biosciences, Inc. is reported to have a significant shareholder group led by Viking Global entities and individuals O. Andreas Halvorsen and Rose S. Shabet. These reporting persons collectively beneficially own 1,383,621 shares of Common Stock, including shares underlying warrants to purchase 259,692 shares at an exercise price of $0.0001 per share. Based on 14,671,186 shares outstanding as of May 8, 2026 plus the warrant shares, their beneficial ownership represents up to 9.3% of the class. Voting and dispositive powers are held on a shared basis through a complex structure of Delaware and Cayman Islands investment entities managed by Viking Global Investors LP and related general partners.
Inhibrx Biosciences, Inc. reported second quarter 2026 results with a net loss of $36.7 million, or $2.34 per share, compared to a net loss of $28.7 million a year earlier. The company reported no revenue in the quarter versus $1.3 million in Q2 2025.
Research and development expenses were $23.9 million and general and administrative expenses were $8.3 million, both higher than the prior-year period, while total other expense rose to $4.5 million mainly from increased interest on debt. As of June 30, 2026, cash and cash equivalents were $133.3 million; including proceeds from a July loan amendment, cash reached $219.5 million as of August 6, 2026. A second amendment to the Oxford Finance loan provides up to $325.0 million in additional gross proceeds, of which $100.0 million was funded. The FDA accepted the biologics license application for ozekibart in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027, and the company plans further clinical and regulatory milestones for ozekibart and INBRX-106.